Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Published online 26 January 2008
Haematologica, Vol 93, Issue 2, 287-290 doi:10.3324/haematol.11891
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanada, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanada, M.

Acute Lymphoblastic Leukemia

Karyotype at diagnosis is the major prognostic factor predicting relapse-free survival for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy

Masamitsu Yanada1,, Jin Takeuchi2, Isamu Sugiura3, Hideki Akiyama4, Noriko Usui5, Fumiharu Yagasaki6, Kazuhiro Nishii7, Yasunori Ueda8, Makoto Takeuchi9, Shuichi Miyawaki10, Atsuo Maruta11, Hiroto Narimatsu1, Yasushi Miyazaki12, Shigeki Ohtake13, Itsuro Jinnai6, Keitaro Matsuo14, Tomoki Naoe1, Ryuzo Ohno14 for the Japan Adult Leukemia Study Group

1 From the Nagoya University Graduate School of Medicine, Nagoya;
2 Nihon University School of Medicine, Tokyo;
3 Toyohashi Municipal Hospital, Toyohashi;
4 Tokyo Metropolitan Komagome Hospital, Tokyo;
5 Jikei University School of Medicine, Tokyo;
6 Saitama Medical University, Saitama;
7 Mie University School of Medicine, Tsu;
8 Kurashiki Central Hospital, Kurashiki;
9 National Hospital Organization Minami-Okayama Medical Center, Okayama;
10 Saiseikai Maebashi Hospital, Maebashi;
11 Kanagawa Cancer Center, Yokohama;
12 Nagasaki University Graduate School of Biomedical Sciences, Nagasaki;
13 Kanazawa University Graduate School of Medical Science, Kanazawa;
14 Aichi Cancer Center, Nagoya, Japan

Correspondence: Masamitsu Yanada, MD, Department of Leukemia, Unit 428, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA. E-mail: myanada{at}mdanderson.org


   ABSTRACT
TOP
 ABSTRACT
Introduction
 Design and Methods
 Results and Discussion
 References
 
To identify factors associated with relapse-free survival (RFS), 80 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia, enrolled in a phase II study of imatinib-combined chemotherapy, were analyzed. The median follow-up of surviving patients was 26.7 months (maximum, 52.5 months). Twenty-eight out of 77 patients who had achieved CR relapsed. The probability of RFS was 50.5% at 2 years. Multivariate analysis revealed that the presence of secondary chromosome aberrations in addition to t(9;22) at diagnosis constitute an independent predictive value for RFS (p=0.027), and increase the risk of treatment failure by 2.8-fold.

Key words: acute lymphoblastic leukemia, Philadelphia chromosome, BCR-ABL, imatinib, karyotype.


   Introduction
TOP
 ABSTRACT
 Introduction
Design and Methods
 Results and Discussion
 References
 
The treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) has changed dramatically since imatinib, a selective inhibitor of the ABL tyrosine kinase, was introduced.1,2 Combined with chemotherapy, or even as a single agent, it can produce complete remission (CR) rates of 90% or higher in newly diagnosed patients.3–9 We previously reported the results of a phase II study by the Japan Adult Leukemia Study Group (JALSG) to test the efficacy and feasibility of imatinib-combined chemotherapy for newly diagnosed Ph+ ALL.6 The rate of CR reached 96%, and that of BCR-ABL negativity in bone marrow 71%. However, despite a relatively short follow-up period, relapse occurred in a subset of the patients who had achieved CR.

On the other hand, remarkable progress is being made with the development of novel tyrosine kinase inhibitors with more potent in vitro and in vivo activities than imatinib.10,11 Given this, we investigated factors associated with relapse-free survival (RFS).


   Design and Methods
TOP
 ABSTRACT
 Introduction
 Design and Methods
Results and Discussion
 References
 
Patients and treatments
Eligibility criteria included newly diagnosed Ph+ ALL, age between 15 and 64 years, an Eastern Co-operative Oncology Group performance status between 0 and 3, and adequate liver, kidney and heart function. Written informed consent was obtained from all patients prior to registration.

For remission induction therapy, imatinib was administered from day 8 to day 63 in combination with daunorubicin, cyclophosphamide, vincristine (VCR) and prednisolone (PSL). Consolidation therapy consisted of an odd course (C1) comprising high-dose methotrexate, high-dose cytarabine and methylprednisolone, and an even course (C2) with single-agent imatinib for 28 days. C1 and C2 were alternated for 4 cycles each. After completion of the consolidation therapy, patients received maintenance therapy consisting of VCR, PSL and imatinib for up to 2 years from the date CR had been achieved.6 The daily dose of imatinib used in this study was 600 mg. Allogeneic hematopoietic stem cell transplantation (HSCT) was recommended if a matched sibling donor was available, and was allowed from an alternative donor.

The protocol was reviewed and approved by the institutional review board of each of the participating centers and was conducted in accordance with the Declaration of Helsinki.

Cytogenetic and molecular analysis
At diagnosis, bone marrow samples were examined for cytogenetic abnormalities with standard banding techniques. Karyotypes were classified according to the International System for Human Cytogenetic Nomenclature.12 The number of BCR-ABL copies in bone marrow was determined at a central laboratory with the real-time quantitative RT-PCR test according to the previously described method.13

Statistical analysis
Kaplan-Meier survival analysis was performed to estimate the probabilities of RFS, event-free survival (EFS), and overall survival (OS), with differences between the groups compared by the log-rank test. Cumulative incidences of relapse were calculated with non-relapse mortality considered as a competing risk, and differences between the groups were compared with the Gray’s test. For risk factor analysis, a Cox proportional hazards model was constructed. In multivariate analysis, variables with p values of <0.10 determined by univariate analysis were included in the final model. A hazard ratio (HR) was calculated in conjunction with a 95% confidence interval (CI).


   Results and Discussion
TOP
 ABSTRACT
 Introduction
 Design and Methods
 Results and Discussion
References
 
A total of 80 patients were recruited between September 2002 and January 2005. The median age was 48 years (range 15–63), with 49 males and 31 females. CR was achieved by 77 (96.2%) patients. During a median follow-up of 26.7 months (maximum 52.5 months), 28 patients relapsed. Of the 17 relapses observed during the consolidation therapy, 13 occurred during the imatinib course. The probabilities of EFS and OS were 48.5±5.7% and 58.1±5.7% at 2 years (Figure 1). For patients who had achieved CR, the probability of RFS was 50.5±5.9% at 2 years. Allogeneic HSCT was performed for 60 patients, including 24 from a sibling donor, 1 from a related donor other than a sibling, 25 from an unrelated donor, and 10 from unrelated cord blood. Disease status at the time of transplantation was first CR for 44 patients, second CR for 4 and non-CR for 12. The 2-year RFS for those who had undergone allogeneic HSCT during first CR was 62.6±7.5% and 62.1±12.3% for those who had not undergone allogeneic HSCT. When allogeneic HSCT was considered as a time-dependent covariate, it was shown to have no significant effect on RFS (HR, 1.03; 95% CI, 0.51–2.09; p=0.934). Major and minor BCR-ABLs were detected in 23 and 56 patients respectively. The transcript type of the remaining patient could not be determined because fluorescent in situ hybridization analysis was used instead of the PCR test. Neither transcript types nor copy numbers at diagnosis were associated with RFS (p=0.763 and 0.912). Pre-treatment cytogenetic results were not available for 4 patients because analysis was not performed (n=2) or was not successful (n=2). Of the remaining 76 patients, 22 showed only t(9;22) or variant translocations, 51 showed additional chromosome aberrations, and 3 showed normal karyotype. Additional aberrations exceeding a frequency of 10% comprised +der(22)t(9;22) in 17 patients, abnormalities involving the short arm of chromosome 9 [abn(9p)] in 17, monosomy 7 in 10, and trisomy 8 in 10. Figure 2 compares RFS for patients with and without additional chromosome aberrations. The presence of additional aberrations was significantly associated with shorter RFS (p=0.003). The relapse rate was also higher in patients with additional aberrations (41% vs. 20% at 2 years, p=0.0414). Analyses of the 4 recurrent abnormalities mentioned above demonstrated a statistically significant negative impact on RFS for +der(22)t(9;22) and abn(9p) (p<0.001 and p=0.005). Even after allogeneic HSCT, patients with additional aberrations appeared to have a trend for shorter RFS than those without (p=0.080), but this might reflect a larger proportion of transplantation beyond first CR in the former (31% vs. 17%). In patients allografted during first CR, there was no difference in cumulative incidences of relapse dated from the day of transplantation between the 2 groups (16.5% vs. 12.5% at 2 years, p=0.546). Variables that showed a significant effect on RFS in the univariate Cox model included additional chromosome aberrations (p=0.005), peripheral blood blasts % (p=0.024) and sex (p=0.03). Results of multivariate analysis are shown in Table 1. The presence of additional chromosome aberrations was identified as the only independent prognostic factor for RFS (p=0.027). These updated data strongly support recent reports showing the feasibility and remarkable efficacy of imatinib-combined chemotherapy for newly diagnosed Ph+ ALL.3–9,14,15 The main objective of this report was to identify factors affecting RFS, an issue of rapidly increasing importance given the development of novel tyrosine kinase inhibitors which are expected to further expand the treatment options for this disease. Our data indicated that additional chromosome aberrations, particularly +der(22)t(9;22) and abn(9p), were associated with shorter RFS. It is well known that additional chromosome aberrations are seen frequently in Ph+ ALL. Before the imatinib era, some groups reported the prognostic relevance of additional aberrations.16–18 By contrast, from a large series of 204 patients, Moorman et al.19 recently showed no significant effect of specific additional aberrations, including +der(22)t(9;22) and del(9p), on survival. In this study, analyzing patients treated with imatinib-combined chemotherapy, the 2-year RFS rate exceeded 80% for those without additional aberrations, whereas outcomes for those with additional aberrations were relatively unfavorable.


Figure 193287
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Kaplan-Meier curves for event-free and overall survival. The probabilities of event-free and overall survival at 2 years were 48.5% and 58.1% respectively (n=80).

 

Figure 293287
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2. Relapse-free survival for patients with and without additional cytogenetic aberrations. Patients with additional cytogenetic aberrations (n=50) had significantly shorter relapse-free survival than those without (n=20).

 

View this table:
[in this window]
[in a new window]
[Download PPT slide]
  		Table 1. Multivariate analysis of factors associated with relapse-free survival.

 
Acquisition of resistance to imatinib is an emerging problem in the treatment of chronic myeloid leukemia. One of the most common mechanisms of resistance is the mutation involving the ABL kinase domain. Although it has not been confirmed whether such mutations compromise the clinical outcome of Ph+ ALL patients treated with imatinib-combined chemotherapy, our observation that most of the early relapses occurred during the consolidation courses consisting of imatinib alone implies possible imatinib resistance. If that is the case, switching from imatinib to other novel tyrosine kinase inhibitors based on the pre-treatment cytogenetic results soon after achieving CR or even earlier could be an alternative treatment approach for further improving outcome in Ph+ ALL. Lack of mutation analysis is a major limitation of this study. Recently, Pfeifer et al.20 studied the ABL kinase domain mutation status in newly diagnosed Ph+ ALL patients who were treated with imatinib-combined chemotherapy, and showed that even before exposure to imatinib, mutations were detected in 38% of patients. Importantly, the frequency of the mutant allele was low in such patients. However, at the time of relapse, the same mutation was present as the dominant clone in 90% of the relapsing cases.20 Altogether, further insights will be provided by investigating the association between karyotype and mutation status at diagnosis.

Despite such limitations, the analysis of 80 patients entered into a single trial identified karyotype at diagnosis as a significant prognostic factor for RFS in newly diagnosed Ph+ ALL patients treated with imatinib-combined chemotherapy. Although our results need to be confirmed regarding kinase domain mutation status, these findings may play a critical role in the future treatment of Ph+ ALL.


   Acknowledgments
 
we wish to thank all physicians and staff at the JALSG participating centers. We also thank Dr. Masayuki Towatari for his outstanding contribution to the launching of this study. Imatinib used in this study was kindly provided by Novartis Pharmaceuticals (Basel, Switzerland)


   Footnotes
 
Authorship and Disclosures

MY designed and co-ordinated the study, analyzed the data, and wrote the paper; JT, NU, FY, SM, and IJ designed the study, and provided patient sample and clinical data; IS, HA, KN, YU, MT, and AM provided patient sample and clinical data; HN co-ordinated the study, and revised the paper. YM provided patient sample and clinical data, and engaged in data management. SO designed the study, provided patient sample and clinical data, and engaged in data management; KM designed the study, and analyzed the data; TN chaired the study group, co-ordinated the study, and revised the paper; RO served as the principal investigator, chaired the study group, and revised the paper. All authors reviewed the paper, interpreted the results, and approved the final version. The authors reported no potential conflicts of interest.

Funding: this work was supported in part by a government grant for the Cancer Translational Research Project from the Japanese Ministry of Education, Culture, Sports, Science, and Technology.

Received for publication June 25, 2007. Accepted for publication November 20, 2007.


   References
TOP
 ABSTRACT
 Introduction
 Design and Methods
 Results and Discussion
 References
 

  1. Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2005;118-22.
  2. Yanada M, Naoe T. Imatinib combined chemotherapy for Philadelphia chromosome-positive acute lymphoblastic leukemia: major challenges in current practice. Leuk Lymphoma 2006;47:1747-53.[CrossRef][Web of Science][Medline]
  3. Thomas DA, Faderl S, Cortes J, O'Brien S, Giles FJ, Kornblau SM, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004;103:4396-407.[Abstract/Free Full Text]
  4. Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I, Takeuchi M, et al. Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood 2004;104:3507-12.[Abstract/Free Full Text]
  5. Lee KH, Lee JH, Choi SJ, Lee JH, Seol M, Lee YS, et al. Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia 2005;19:1509-16.[CrossRef][Web of Science][Medline]
  6. Yanada M, Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006;24:460-6.[Abstract/Free Full Text]
  7. Wassmann B, Pfeifer H, Goekbuget N, Beelen DW, Beck J, Stelljes M, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL). Blood 2006;108:1469-77.[Abstract/Free Full Text]
  8. Vignetti M, Fazi P, Cimino G, Martinelli G, Di Raimondo F, Ferrara F, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood 2007;109:3676-8.[Abstract/Free Full Text]
  9. Ottmann OG, Wassmann B, Pfeifer H, Giagounidis A, Stelljes M, Duhrsen U, et al. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Cancer 2007;109:2068-76.[CrossRef][Medline]
  10. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.[Abstract/Free Full Text]
  11. Kantarjian H, Giles F, Wunderle L, Bhalla K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.[Abstract/Free Full Text]
  12. Mitelman F, et al. ISCN 1995: An International System for Human Cytogenetic Nomenclature, Basel, Switzerland: S Karger. 1995.
  13. Osumi K, Fukui T, Kiyoi H, Kasai M, Kodera Y, Kudo K, et al. Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk Lymphoma 2002;43:2291-9.[CrossRef][Web of Science][Medline]
  14. Lee S, Kim YJ, Min CK, Kim HJ, Eom KS, Kim DW, et al. The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2005;105:3449-57.[Abstract/Free Full Text]
  15. de Labarthe A, Rousselot P, Huguet-Rigal F, Delabesse E, Witz F, Maury S, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 2007;109:1408-13.[Abstract/Free Full Text]
  16. Rieder H, Ludwig WD, Gassmann W, Maurer J, Janssen JW, Gokbuget N, et al. Prognostic significance of additional chromosome abnormalities in adult patients with Phila-delphia chromosome positive acute lymphoblastic leukaemia. Br J Haematol 1996;95:678-91.[CrossRef][Web of Science][Medline]
  17. Thomas X, Thiebaut A, Olteanu N, Danaila C, Charrin C, Archimbaud E, et al. Philadelphia chromosome positive adult acute lymphoblastic leukemia: characteristics, prognostic factors and treatment outcome. Hematol Cell Ther 1998;40:119-28.[Web of Science][Medline]
  18. Wetzler M, Dodge RK, Mrozek K, Stewart CC, Carroll AJ, Tantravahi R, et al. Additional cytogenetic abnormalities in adults with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a study of the Cancer and Leukaemia Group B. Br J Haematol 2004;124:275-88.[CrossRef][Web of Science][Medline]
  19. Moorman AV, Harrison CJ, Buck GA, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007;109:3189-97.[Abstract/Free Full Text]
  20. Pfeifer H, Wassmann B, Pavlova A, Wunderle L, Oldenburg J, Binckebanck A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood 2007;110:727-34.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 BloodHome page
A. K. Fielding, J. M. Rowe, S. M. Richards, G. Buck, A. V. Moorman, I. J. Durrant, D. I. Marks, A. K. McMillan, M. R. Litzow, H. M. Lazarus, et al.
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993
Blood, May 7, 2009; 113(19): 4489 - 4496.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. M. O'Brien, D. A. Thomas, and S. Faderl
A La Carte Therapy of Specific Acute Lymphocytic Leukemia Subsets
ASCO Educational Book, January 1, 2009; 2009(1): 365 - 370.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yanada, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yanada, M.

HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS